U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H14N4O
Molecular Weight 266.2984
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NEVIRAPINE

SMILES

Cc1ccnc2c1N=C(c3cccnc3N2C4CC4)O

InChI

InChIKey=NQDJXKOVJZTUJA-UHFFFAOYSA-N
InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/nevirapine.html

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time. Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. Nevirapine is used for use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.

CNS Activity

Curator's Comment:: Nevirapine (NVP) crosses well the BBB

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL614530
239.0 µM [EC50]
0.31 nM [EC50]
250.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Viramune

Approved Use

VIRAMUNE is an NNRTI indicated for combination antiretroviral treatment of HIV-1 infection

Launch Date

8.2036798E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2060 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEVIRAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
82000 ng × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NEVIRAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
96700 ng × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
NEVIRAPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
161000 ng × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEVIRAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
45 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEVIRAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
40%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEVIRAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg single, oral
Overdose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy, 8-days-old
n = 1
Health Status: unhealthy
Age Group: 8-days-old
Sex: F
Population Size: 1
Sources:
Other AEs: Neutropenia, Hyperlactatemia...
Other AEs:
Neutropenia (mild)
Hyperlactatemia
Sources:
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Disc. AE: Rash, Stevens-Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Rash (2%)
Stevens-Johnson syndrome (1%)
Transaminases increased (1%)
ALT increased (1%)
GGT increased (<1%)
AST increased (<1%)
Hepatic enzyme increased (<1%)
Hepatitis (1%)
Hepatotoxicity (1%)
Hepatitis acute (<1%)
Hepatitis toxic (<1%)
Nausea (1%)
Malaise (1%)
Pyrexia (1%)
Fatigue (1%)
Vascular disorders (<1%)
Sources: Page: p. 56
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Disc. AE: Rash, Drug rash with eosinophilia and systemic symptoms...
AEs leading to
discontinuation/dose reduction:
Rash (2%)
Drug rash with eosinophilia and systemic symptoms (<1%)
Transaminases increased (1%)
ALT increased (<1%)
GGT increased (<1%)
AST increased (<1%)
Hepatic enzyme increased (<1%)
Hepatitis (1%)
Hepatotoxicity (<1%)
Hepatitis acute (<1%)
Hepatitis toxic (<1%)
Nausea (<1%)
Malaise (<1%)
Pyrexia (<1%)
Fatigue (<1%)
Vascular disorders (<1%)
Musculoskeletal and connective tissue disorders (<1%)
Sources: Page: p. 56
800 mg 1 times / day multiple, oral
Overdose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, adult
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
Disc. AE: Hepatotoxicity, Reaction skin...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity (grade 5)
Reaction skin (severe)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hyperlactatemia
200 mg single, oral
Overdose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy, 8-days-old
n = 1
Health Status: unhealthy
Age Group: 8-days-old
Sex: F
Population Size: 1
Sources:
Neutropenia mild
200 mg single, oral
Overdose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy, 8-days-old
n = 1
Health Status: unhealthy
Age Group: 8-days-old
Sex: F
Population Size: 1
Sources:
ALT increased 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Fatigue 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Hepatitis 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Hepatotoxicity 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Malaise 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Nausea 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Pyrexia 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Stevens-Johnson syndrome 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Transaminases increased 1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Rash 2%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
AST increased <1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
GGT increased <1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Hepatic enzyme increased <1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Hepatitis acute <1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Hepatitis toxic <1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Vascular disorders <1%
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 506
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 506
Sources: Page: p. 56
Hepatitis 1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Transaminases increased 1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Rash 2%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
ALT increased <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
AST increased <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Drug rash with eosinophilia and systemic symptoms <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Fatigue <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
GGT increased <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Hepatic enzyme increased <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Hepatitis acute <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Hepatitis toxic <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Hepatotoxicity <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Malaise <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Musculoskeletal and connective tissue disorders <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Nausea <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Pyrexia <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Vascular disorders <1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 56
unhealthy, >18 years
n = 505
Health Status: unhealthy
Age Group: >18 years
Sex: M+F
Population Size: 505
Sources: Page: p. 56
Hepatotoxicity grade 5
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
Reaction skin severe
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors.
2001
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
2001
Rwanda to receive cheaper anti-HIV drugs for chronic treatment and free viramune to prevent viral transmission from mother to child.
2001 Apr
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.
2001 Apr
Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.
2001 Apr
Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome.
2001 Apr 1
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
2001 Apr 13
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.
2001 Apr 13
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
2001 Apr 15
Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine.
2001 Apr 15
[Highly active antiretroviral therapy with nevirapine. Therapy compliance determines success].
2001 Apr 2
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
2001 Apr 2
Antiviral drugs: current state of the art.
2001 Aug
South Africa cuts agreement for one AIDS drug but ignores another.
2001 Feb
Revised nevirapine insert.
2001 Feb
Galactorrhoea, hyperprolactinaemia, and protease inhibitors.
2001 Feb 10
South Africa's AIDS activists say new neviripine programme is not enough.
2001 Feb 10
Indian company offers cheap anti-AIDS drugs.
2001 Feb 15
Drug interaction between St John's wort and nevirapine.
2001 Feb 16
Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography.
2001 Feb 25
Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds.
2001 Feb 26
Prevention of nevirapine-associated rash.
2001 Feb 3
Further views by the Erice working group on mother-to-child transmission of HIV type 1.
2001 Jan
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
2001 Jan
Pharmacokinetic of nevirapine in haemodialysis.
2001 Jan
From the Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
2001 Jan 24-31
Need for increased dose of warfarin in HIV patients taking nevirapine.
2001 Jan 26
New developments in anti-HIV chemotherapy.
2001 Jan-Feb
Sequence-specific detection of individual DNA strands using engineered nanopores.
2001 Jul
Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors.
2001 Jul
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
2001 Jul 1
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
2001 Jul 6
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
2001 Jul 6
Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
2001 Jun
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART.
2001 Jun
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine.
2001 Jun
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
2001 Jun 1
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
2001 Jun 15
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
2001 Jun 15
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
2001 Jun 15
South Africa in crisis on HIV/AIDS treatment.
2001 Jun 29
[Nevirapine and clinical withdrawal syndrome].
2001 Mar
Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.
2001 Mar
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
2001 Mar 1
Efficiency comparisons of rank and permutation tests based on summary statistics computed from repeated measures data.
2001 Mar 15
Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1.
2001 Mar 3
Sequencing antiretroviral drugs.
2001 Mar 30
[Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients].
2001 Mar 31
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.
2001 May 4
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.
2001 Sep
Patents

Sample Use Guides

In Vivo Use Guide
The recommended dose for Nevirapine is one 200 mg tablet daily for the first 14 days, followed by one 200 mg tablet twice daily, in combination with other antiretroviral agents.
Route of Administration: Oral
The IC50 value for inhibition by nevirapine against immunodeficiency virus type 1 (HIV) nucleoside reverse transcriptase (RT) in removal assay was 3 uM
Name Type Language
NEVIRAPINE
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
NEVIRAPINE ANHYDROUS [USP-RS]
Common Name English
VIRAMUNE
Brand Name English
NEVIRAPINE [MI]
Common Name English
NEVIRAPINE, ANHYDROUS [EP]
Common Name English
NEVIRAPINE [EP MONOGRAPH]
Common Name English
NEVIRAPINE [USP]
Common Name English
NEVIRAPINE TEVA
Brand Name English
NEVIRAPINUM ANHYDROUS [WHO-IP LATIN]
Common Name English
NSC-641530
Code English
NEVIRAPINE [MART.]
Common Name English
NEVIRAPINE [INN]
Common Name English
NEVIRAPINE ANHYDROUS [WHO-IP]
Common Name English
NEVIRAPINE, ANHYDROUS
EP  
Common Name English
BIRG-0587
Code English
NEVIRAPINE [EMA EPAR]
Common Name English
NEVIRAPINE [VANDF]
Common Name English
BIRG 0587
Code English
NEVIRAPINE [JAN]
Common Name English
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B:2',3'-E)(1,4)DIAZEPIN-6-ONE
Systematic Name English
NEVIRAPINE [USP MONOGRAPH]
Common Name English
6H-DIPYRIDO(3,2-B:2',3'-E)(1,4)DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-
Systematic Name English
NEVIRAPINE [WHO-DD]
Common Name English
NEVIRAPINE [HSDB]
Common Name English
NEVIRAPINE [USAN]
Common Name English
NEVIRAPINE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS NEVIRAPINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
NCI_THESAURUS C97453
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
WHO-ATC J05AR05
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
WHO-VATC QJ05AG01
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
NDF-RT N0000175463
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
EMA ASSESSMENT REPORTS VIRAMUNE (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
LIVERTOX 679
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.2
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
WHO-VATC QJ05AR07
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
NDF-RT N0000009948
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
NDF-RT N0000175460
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/NEV/STA)
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
WHO-ATC J05AG01
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
FDA ORPHAN DRUG 293409
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/NEV/ZID)
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
WHO-VATC QJ05AR05
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
WHO-ATC J05AR07
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
Code System Code Type Description
EVMPD
SUB09214MIG
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
NDF-RT
N0000190118
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY Cytochrome P450 3A Inducers [MoA]
EPA CompTox
129618-40-2
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
RXCUI
53654
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY RxNorm
LACTMED
Nevirapine
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
EVMPD
SUB25191
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
INN
6815
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
WIKIPEDIA
NEVIRAPINE
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
ChEMBL
CHEMBL57
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
MESH
D019829
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
MERCK INDEX
M7845
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY Merck Index
CAS
129618-40-2
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
USP_CATALOG
1460703
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY USP-RS
WHO INTERNATIONAL PHARMACOPEIA
NEVIRAPINE
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY Description: A white to almost white powder. Solubility: Practically insoluble in water, sparingly to slightly soluble in dichloromethane R, slightly soluble in methanol R. Category: Antiretroviral (Non-Nucleoside Reverse Transcriptase Inhibitor). Storage: Nevirapine should be kept in a well-closed container. Labelling: The designation on the container should state whether the substance is the hemihydrate or is in the anhydrous form. Definition: Nevirapine contains not less than 98.0% and not more than 102.0% of nevirapine (C15H14N4O), calculated with reference to the anhydrous substance.
DRUG BANK
DB00238
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
DRUG CENTRAL
1904
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
NCI_THESAURUS
C29277
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
PUBCHEM
4463
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
HSDB
7164
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY
NDF-RT
N0000187064
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY Cytochrome P450 2B6 Inducers [MoA]
FDA UNII
99DK7FVK1H
Created by admin on Fri Jun 25 20:56:11 UTC 2021 , Edited by admin on Fri Jun 25 20:56:11 UTC 2021
PRIMARY